S
Stephanie O. Klopfer
Researcher at Merck & Co.
Publications - 26
Citations - 1423
Stephanie O. Klopfer is an academic researcher from Merck & Co.. The author has contributed to research in topics: Rubella & Vaccination. The author has an hindex of 11, co-authored 26 publications receiving 1224 citations.
Papers
More filters
Journal ArticleDOI
Optimal Full Matching and Related Designs via Network Flows
TL;DR: In this paper, the authors present an algorithm for exploring the intermediate territory, given requirements on matched sets' uniformity in X and dispersion in Z, the algorithm first decides the requirements' feasibility and then furnishes a match that is optimal for X-uniformity among matches with Z-dispersion as stipulated.
Journal ArticleDOI
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial
Jürgen K. Rockstroh,Mark T. Nelson,Christine Katlama,J. Lalezari,Josep Mallolas,Mark Bloch,Gail V. Matthews,Michael S. Saag,Philippe J. Zamor,Chloe Orkin,Jacqueline Gress,Stephanie O. Klopfer,Melissa Shaughnessy,Janice Wahl,Bach-Yen Nguyen,Eliav Barr,Heather L. Platt,Michael N. Robertson,Mark S. Sulkowski +18 more
TL;DR: This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis, and these data are consistent with previous trials of this regimen in the monoinfected population.
Journal ArticleDOI
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin
Thomayant Prueksaritanont,Xiaoyan Chu,Raymond Evers,Stephanie O. Klopfer,Luzelena Caro,Prajakti A. Kothare,Cynthia Dempsey,Scott Rasmussen,Robert Houle,Grace Chan,Xiaoxin Cai,Robert Valesky,Iain P. Fraser,S. Aubrey Stoch +13 more
TL;DR: It is indicated that pitavastatin is a more sensitive and selective and thus preferred clinical OATP1B probe substrate than rosuvastatin, and that a single IV dose of rifampicin is aMore selective OATp1B inhibitor than a PO dose.
Journal ArticleDOI
Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children
Henry R. Shinefield,Steve Black,Laura Digilio,Keith S. Reisinger,Mark M. Blatter,Jacqueline Gress,Michelle L Brown,Karen Eves,Stephanie O. Klopfer,Florian Schödel,Barbara J. Kuter +10 more
TL;DR: A 1- or 2-dose regimen of MMRV is generally well-tolerated when administered to 12- to 23-month-old children and has a safety and immunogenicity profile similar to that of M-M-R®II and VARIVAX administered concomitantly.
Journal ArticleDOI
Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults
Nancy F. Crum-Cianflone,Kenneth Wilkins,Andrew W. Lee,Anthony D. Grosso,Michael L. Landrum,Michael L. Landrum,Amy C. Weintrob,Amy C. Weintrob,Anuradha Ganesan,Jason D. Maguire,Jason D. Maguire,Stephanie O. Klopfer,Carolyn Brandt,Carolyn Brandt,William P. Bradley,Mark R. Wallace,Brian K. Agan +16 more
TL;DR: Most adults with well-controlled HIV infections had durable seropositive responses up to 6-10 years after HAV vaccination, and suppressed HIV RNA levels are associated with durable HAV responses.